Last reviewed · How we verify
NCT04472624: RESET-PKD
Short Term Induction of Ketosis in PKD
NA trial testing Fasting in ADPKD in 10 participants. Completed in 1 July 2021.
1 July 2021
Quick facts
| Lead sponsor | University of Cologne |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 10 |
| Start date | 1 July 2020 |
| Primary completion | 1 July 2021 |
| Estimated completion | 1 July 2021 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Fasting
- Ketogenic diet — full drug profile →
Conditions studied
- ADPKD — all drugs for ADPKD →
Sponsor
University of Cologne
Who can join
Adults 18 to 60, any sex, with ADPKD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recently, it has been shown that ketose-inducing dietary interventions slow disease progression in animal models of polycystic kidney disease (PKD), even when the state of ketosis is only induced for a short period of time. The present study aims to investigate the effects of short term ketosis on total kidney volume (TKV) (and other parameters) in 10 ADPKD-patients with rapidly progressive disease.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease.
Oehm S, Steinke K, Schmidt J, Arjune S, et al · · 2023 · cited 28× · PMID 36423335 · DOI 10.1093/ndt/gfac311 -
Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.
Benz EG, Hartung EA. · · 2021 · cited 20× · PMID 33474686 · DOI 10.1007/s00467-020-04869-w -
Metabolic Changes in Polycystic Kidney Disease as a Potential Target for Systemic Treatment.
Haumann S, Müller RU, Liebau MC. · · 2020 · cited 12× · PMID 32847032 · DOI 10.3390/ijms21176093 -
Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD.
Knol MGE, Bais T, Geertsema P, Connelly MA, et al · · 2024 · cited 9× · PMID 37974030 · DOI 10.1093/ndt/gfad239 -
Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't.
Ong ACM, Torra R. · · 2022 · cited 9× · PMID 35664267 · DOI 10.1093/ckj/sfac103 -
Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD.
Pagliarini R, Podrini C. · · 2021 · cited 8× · PMID 34901057 · DOI 10.3389/fmed.2021.740087 -
Obesity, Weight Loss, Lifestyle Interventions, and Autosomal Dominant Polycystic Kidney Disease.
Steele C, Nowak K. · · 2022 · cited 6× · PMID 35350649 · DOI 10.3390/kidneydial2010013 -
Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease.
Steele CN, Nowak KL. · · 2023 · cited 2× · PMID 37088524 · DOI 10.1053/j.akdh.2022.12.008
Verify or expand the search:
- PubMed search for NCT04472624
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fasting
Trials testing the same drug.
- NCT07216989 — Fastomics: Metabolic and Therapeutic Effects of Prolonged Fasting · recruiting
- NCT06826924 — 7-Days Water-Only Fasting Trial in Prostate Cancer · NA · recruiting
- NCT07009288 — A Study of Time-Restricted Eating in Childhood Cancer Survivors · NA · recruiting
- NCT06963437 — Interventions for Weight Regain After Bariatric Surgery · NA · completed
- NCT07178106 — Investigation of the Relationship Between Peripheral and Central Metabolic Changes Caused by Fasting · NA · completed
Other recruiting trials for ADPKD
Currently open trials in the same condition.
- NCT05014178 — Kidney Sodium Functional Imaging · recruiting
- NCT06759142 — Analysis of Patients With Autosomal Dominant Polycystic Kidney · recruiting
- NCT04338048 — Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study · recruiting
- NCT03273413 — Statin Therapy in Patients With Early Stage ADPKD · Phase 4 · active not recruiting
- NCT06416761 — Genetics in the Progression of Nephropathies · recruiting
Other University of Cologne trials
Trials by the same sponsor.
- NCT07280585 — STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease · Phase 3 · recruiting
- NCT06612515 — Vaccine-induced Immunity in Immunocompromised Patients · recruiting
- NCT06781710 — Analysis of the Epidemiology, Clinical Presentation and Therapy as Well as Therapy-associated Risk of Demyelination Synd · recruiting
- NCT05969431 — Hair Cortisol as Marker of Chronic Stress in Preterm and Term Fathers - Fathair-study · recruiting
- NCT05876221 — Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04472624 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cologne
- Last refreshed: 14 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04472624.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing